Effect of Regdanvimab on Mortality in Patients Infected with SARS-CoV-2 Delta Variants: A Propensity Score-Matched Cohort Study
Soyoon Hwang, Nan Young Lee, Eunkyung Nam, Yu Kyung Kim, Shin-Woo Kim, Hyun-Ha Chang, Yoonjung K Kim, Sohyun Bae, Juhwan Jeong, Jae-Ho Shin, Guehwan Jang, Changhee Lee, Ki Tae Kwon
Infectious Diseases and Therapy, doi:10.1007/s40121-024-00971-w
Introduction: Regdanvimab, a monoclonal antibody pharmaceutical, is the first Korean drug approved for treating coronavirus disease 2019 . We analyzed the therapeutic efficacy of regdanvimab in patients with the COVID-19 delta variant infection.
Methods: We retrospectively reviewed the electronic medical records of patients hospitalized at two Korean tertiary COVID-19 hospitals with COVID-19 delta variant infection between May 26, 2021, and January 30, 2022. To analyze the therapeutic efficacy of regdanvimab, the patients were divided into regdanvimab and non-regdanvimab groups and were 1:1 propensity-score (PS)-matched on age, severity at admission, and COVID-19 vaccination history. Results: Of 492 patients, 262 (53.3%) and 230 (46.7%) were in the regdanvimab and non-regdanvimab groups, respectively. After PS matching the groups on age, severity at admission, and COVID-19 vaccination history, each group comprised 189 patients. The 30-day hospital
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Aggarwal, Stella, Walker, SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern, medRxiv
Alexandar, Ravisankar, Kumar, Jakkan, A comprehensive review on Covid-19 delta variant, Int J Pharmacol Clin Res (IJPCR)
Deb, Molla, Saif-Ur-Rahman, An update to monoclonal antibody as therapeutic option against COVID-19, Biosaf Health
Greaney, Starr, Gilchuk, Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition, Cell Host Microbe
Holland, Kellett, A systematic review of the discrimination and absolute mortality predicted by the National Early Warning Scores according to different cut-off values and prediction windows, Eur J Intern Med
Hurt, Wheatley, Neutralizing antibody therapeutics for COVID-19, Viruses
Jacobs, Haidar, Mellors, COVID-19: challenges of viral variants, Ann Rev Med
Jang, Oh, Kim, Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the delta variant, Int J Infect Dis
Khedar, Mittal, Ambaliya, Greater Covid-19 severity and mortality in hospitalized patients in second (delta variant) wave compared to the first: single centre prospective study in India, medRxiv
Kim, Jang, Lee, Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study, Front Cell Infect Microbiol
Kim, Ryu, Lee, A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein, Nat Commun
Kodera, Rashed, Hirata, Estimation of realworld vaccination effectiveness of mRNA COVID-19 vaccines against delta and omicron variants in Japan, Infect Dis Ther
Kwak, Song, Kang, Use of the monoclonal antibody regdanvimab to treat patients hospitalized with COVID-19: real-world data during the delta variant predominance, Infect Chemother
Lee, Park, Early oxygen requirement in patients with wild-to-moderate COVID-19 who received regdanvimab after delta-variant outbreak, Infect Chemother
O'horo, Challener, Speicher, Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the delta variant, Mayo Clin Proc
Park, Lim, Kim, Clinical and virological characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.617.2 (delta) variant: a prospective cohort study, Clin Infect Dis
Planas, Saunders, Maes, Considerable escape of SARS-CoV-2 omicron to antibody neutralization, Nature
Ryu, Kang, Noh, The in vitro and in vivo efficacy of CT-P59 against gamma, delta and its associated variants of SARS-CoV-2, Biochem Biophys Res Commun
Silcock, Corfield, Staines, Rooney, Superior performance of National Early Warning Score compared with quick Sepsis-related Organ Failure Assessment Score in predicting adverse outcomes: a retrospective observational study of patients in the prehospital setting, Eur J Emerg Med
Streinu-Cercel, Săndulescu, Preotescu, Efficacy and safety of regdanvimab (CT-P59): a phase 2/3 randomized, double-blind, placebocontrolled trial in outpatients with mild-to-moderate coronavirus disease 2019, Open Forum Infect Dis
Syed, Regdanvimab: First approval, Drugs
Tchang, Askin, Sahagun, The independent risk of obesity and diabetes and their interaction in COVID-19: a retrospective cohort study, Obesity
Tenforde, Self, Gaglani, Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death-United States, March 2021-January 2022, Morb Mortal Wkly Rep
Touret, Baronti, Bouzidi, De Lamballerie, In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B. 1.1. 529 529 isolate, Sci Rep
Twohig, Nyberg, Zaidi, Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study, Lancet Infect Dis
Zali, Khodadoost, Gholamzadeh, Mortality among hospitalized COVID-19 patients during surges of SARS-CoV-2 alpha (B. 1.1. 7) and delta (B. 1. 617. 2) variants, Sci Rep
Zhao, Huang, Zhang, Chen, Gao et al., The global transmission of new coronavirus variants, Environ Res
